$349 Million is the total value of New Leaf Venture Partners, L.L.C.'s 20 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARVN | ARVINAS INC | $76,573,000 | -16.8% | 2,283,048 | 0.0% | 21.97% | -20.2% | |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS INC | $72,236,000 | -15.9% | 1,209,571 | -42.0% | 20.73% | -19.3% |
| PASG | PASSAGE BIO | $68,268,000 | +73.5% | 2,497,922 | 0.0% | 19.59% | +66.4% | |
| HARP | HARPOON THERAPEUTICS INC | $48,495,000 | +43.3% | 2,921,405 | 0.0% | 13.92% | +37.5% | |
| PRNB | Sell | PRINCIPIA BIOPHARMA INC | $14,934,000 | -40.4% | 249,774 | -40.8% | 4.28% | -42.9% |
| APTX | APTINYX INC | $13,720,000 | +93.0% | 3,290,079 | 0.0% | 3.94% | +85.2% | |
| ARAV | ARAVIVE INC | $11,016,000 | +102.1% | 946,423 | 0.0% | 3.16% | +93.8% | |
| ALEC | Sell | ALECTOR INC | $8,299,000 | -46.2% | 339,569 | -46.9% | 2.38% | -48.4% |
| AVRO | AVROBIO INC | $5,506,000 | +12.1% | 315,550 | 0.0% | 1.58% | +7.6% | |
| OBSV | OBSEVA SA | $5,304,000 | +144.4% | 900,501 | 0.0% | 1.52% | +134.5% | |
| SRRA | SIERRA ONCOLOGY INC | $4,956,000 | +23.2% | 409,611 | 0.0% | 1.42% | +18.2% | |
| CMRX | CHIMERIX INC | $4,185,000 | +115.3% | 1,350,000 | 0.0% | 1.20% | +106.4% | |
| CHMA | CHIASMA INC | $3,958,000 | +47.4% | 735,700 | 0.0% | 1.14% | +41.5% | |
| XFOR | X4 PHARMACEUTICALS INC | $3,122,000 | -6.8% | 335,000 | 0.0% | 0.90% | -10.6% | |
| CRNX | CRINETICS PHARMACEUTICALS INC | $2,470,000 | +19.2% | 141,000 | 0.0% | 0.71% | +14.4% | |
| ITRM | ITERUM THERAPEUTICS PLC | $1,733,000 | -56.1% | 1,456,303 | 0.0% | 0.50% | -57.9% | |
| NERV | MINERVA NEUROSCIENCES INC | $1,623,000 | -40.0% | 449,500 | 0.0% | 0.47% | -42.4% | |
| STIM | Sell | NEURONETICS INC | $1,043,000 | -30.7% | 540,317 | -32.2% | 0.30% | -33.7% |
| UMRX | UNUM THERAPEUTICS INC | $826,000 | +11.3% | 1,795,545 | 0.0% | 0.24% | +6.8% | |
| PDSB | PDS BIOTECHNOLOGY CORP | $236,000 | +177.6% | 117,242 | 0.0% | 0.07% | +172.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DECIPHERA THERAPEUTICS INC | 25 | Q3 2023 | 44.4% |
| CHIMERIX INC | 25 | Q1 2023 | 20.9% |
| SIERRA ONCOLOGY INC | 22 | Q2 2022 | 14.9% |
| ARVINAS INC | 21 | Q3 2023 | 44.8% |
| CRINETICS PHARMACEUTICALS INC | 21 | Q3 2023 | 11.4% |
| OBSEVA SA | 20 | Q4 2021 | 8.5% |
| AVROBIO INC | 20 | Q1 2023 | 1.7% |
| HARPOON THERAPEUTICS INC | 19 | Q3 2023 | 20.0% |
| ALECTOR INC | 19 | Q3 2023 | 4.6% |
| ITERUM THERAPEUTICS PLC | 18 | Q3 2022 | 3.8% |
View New Leaf Venture Partners, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-06 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-09 |
| 13F-HR | 2022-05-06 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
View New Leaf Venture Partners, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.